General Mills, Inc. (NYSE:GIS) shares fell nearly 4% Friday morning after the branded consumer foods maker issued downside guidance for Q2 ending November 23, 2014, expecting adjusted diluted earnings of $0.75-$0.77 per share, below the consensus of $0.88 per share. General Mills, Inc. (NYSE:GIS) cited continued weak food industry trends in the U.S. and slowing growth in key emerging markets for the lower outlook.The company said fiscal 2015 adjusted EPS should increase at a low single-digit rate relative to the base of $2.82 per diluted share posted for fiscal 2014 ended on May 2014. Total segment operating profit is expected to decrease at a low single-digit rate from $3.15 billion posted in fiscal 2014. FY2015 revenues are expected to grow at a low single-digit rate relative to the base of $17.9 billion in fiscal 2014. Previously, the company expected mid single-digit growth in revenues and high single-digit growth in adjusted diluted EPS in fiscal 2015. GIS shares were down 3.7% at $51.28 in early morning trade Friday, moving within a 52-week range of $46.70-$55.64.Kodiak Oil & Gas Corp (NYSE:KOG) said that for Q3, or the quarter ended Sept. 30, 2014, revenue fell short of analysts' expectations, while earnings were better than expected. Kodiak Oil & Gas Corp (NYSE:KOG) shares are trading with a 52-week range of $9.28 - $16.29. The independent energy company reported Q3 net income of $92.2 million, or $0.34 per share, compared with the prior-year period's $31.2 million, or $0.12 per share. The Capital IQ analyst estimate is for $0.20 EPS.Revenue was $292.2 million, down 2% from $299.6 million in the same quarter last year. Analysts were expecting revenue of $314.54 million. The company attributed the decline in revenue to a 13% decrease in average crude oil price to $85.35 per barrel in Q3 2014. from $98.19 per barrel in Q3 2013. The company reported overall 14% increase in quarter-over-quarter equivalent sales volumes with 3.7 million barrels of oil equivalent (MMBOE) sold, or an average of 40,485 BOE per day (BOE/d) during Q3, as compared to 3.3 million BOE, or an average of 35,406 BOE/d in the same quarter in 2013. Crude oil revenue accounted for 93% of oil and gas sales recorded during the quarter.CTI BioPharma Corp (NASDAQ:CTIC) is lower after the company priced an underwritten public offering of 35,000 shares of its Series 21 Preferred Stock, at a price to the public of $1,000 per share of Series 21 Preferred Stock. Shares of the biopharmaceutical company are down 13.99% at $2.03, with a 52-week range of $1.60 - $4.25. The gross proceeds to the company from this offering are expected to be $35 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by CTIC.CTI BioPharma Corp (NASDAQ:CTIC) estimates that its net proceeds from the offering after deducting commission and expenses and other estimated offering expenses payable by CTIC will be $32.8 million. CTIC plans to use the net proceeds to advance the commercialization of PIXUVRI (pixantrone), accelerate the pre-commercial activities for pacritinib, expand the number of investigator-sponsored trials for pacritinib to diseases other than myelofibrosis and acute myeloid leukemia and support the advancement of tosedostat toward registration-directed trials, as well as for general corporate purposes, which may include, among other things, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
